Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. - Wikidata - wikimedia - TriplyDB

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.

http://www.wikidata.org/entity/Q39847507

about

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications Efficacy of palifermin in the hematopoietic stem cell transplant setting Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis.Emerging strategies to boost thymic function Oral manifestations in transplant patients CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children Keratinocyte growth factor.Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation.Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis.Platelet lysate mucohadesive formulation to treat oral mucositis in graft versus host disease patients: a new therapeutic approach Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.Palifermin for management of treatment-induced oral mucositis in cancer patients.Treatment of oral mucositis in hematologic patients undergoing autologous or allogeneic transplantation of peripheral blood stem cells: a prospective, randomized study with a mouthwash containing camelia sinensis leaf extract.Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation.Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX.A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens.Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation.Efficacy of palifermin on oral mucositis and acute GVHD after hematopoietic stem cell transplantation (HSCT) in hematology malignancy patients: a meta-analysis of trials.Immunotherapy against invasive fungal diseases in stem cell transplant recipients.Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.

P2860

Q26852139-A643AFA2-5691-496A-8057-8CEE22DA774E Q27021790-D5D6F521-D328-455E-AAC9-B0A22D521286 Q33745865-B09499A6-8C61-456E-88F8-B55F41D51A45 Q33973916-1565C3C2-F19E-4190-B380-6F8526F1CFCB Q35069523-C291C812-F266-41D4-AFBF-5597B7D4C268 Q35608915-D72D89CC-405F-4124-A16B-E0F666186909 Q36403184-B9917CB0-F3FF-4E49-B288-534810B2687D Q37104266-B562313E-297C-4594-949C-BF58C410197A Q37489900-AA9596C6-D128-4BC4-9200-C32E3395208D Q37667340-AA7D63E1-09B0-4D17-BDF1-7CC1888B6C33 Q37854688-CA9A506B-0449-4D3F-87FE-375CC1694403 Q38044278-774E7C57-F416-4201-B01E-049E01265D8D Q38246766-1B95208D-7222-45C8-885B-C5BE1D6E5F0A Q38312087-E37AD4DD-0B61-42A5-B075-E0B560B3A24A Q38384344-A1C4CF57-CA60-4637-88E1-AEF22E44B084 Q40201079-1DCF8F4D-F484-4D8F-B924-0B58126A822E Q40264385-6253F39D-5DD5-4B4E-8FB7-728113FBD490 Q42052507-64E9543B-4CC3-4EE6-BDEA-915A1772C50E Q43080886-20068989-15EB-4497-9792-7FC9D320791A Q43153715-39321D64-0270-4E88-AC5E-6980EC9EE505 Q43198284-6C97B9E5-2E36-4B7A-ACD4-4EBD080737C0 Q43554770-592A9FC2-8C4C-4724-948B-D81892158853 Q44063957-6C4D615B-4278-4369-985F-C44363CC4DA7 Q48339579-A6FB33FB-BC4D-49FC-A320-300199ADE0D6 Q49332936-0F9E33ED-891D-4100-AEE0-AE476494AB3C Q53152606-8A3493DC-263C-4960-8172-7E4718A1D04A Q53666870-FF909B7C-D4CD-40A8-AB8C-AF61E3975B19

P2860

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.

http://www.wikidata.org/entity/Q39847507

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Palifermin reduces incidence a ...... em-cell transplant recipients.

@en

Palifermin reduces incidence a ...... em-cell transplant recipients.

@nl

type

label

Palifermin reduces incidence a ...... em-cell transplant recipients.

@en

Palifermin reduces incidence a ...... em-cell transplant recipients.

@nl

prefLabel

Palifermin reduces incidence a ...... em-cell transplant recipients.

@en

Palifermin reduces incidence a ...... em-cell transplant recipients.

@nl

P1433

Q39847507-49E55EE5-56F8-4AE5-BEA3-51AAB7DCA111

P1476

Q39847507-CB17750A-18AE-441E-BC68-78F7D88F176D

P2093

Q39847507-038E6B51-1384-4C26-87E0-5D6312B0B27D

Q39847507-525F4464-D4F0-40C6-9FDB-4D16DDC430B8

Q39847507-6CD8F2A8-3166-406A-AA61-C40401901B92

Q39847507-735F7695-6636-454E-83E0-3FAC8853EA2F

Q39847507-BEDBC207-7DEF-473B-AFC0-6C7B49C308A0

Q39847507-C5211A7A-CBA6-4EDD-89A0-A7338CE7F7C2

Q39847507-DD55B9C2-B4AE-4757-8B43-CF85980291F6

Q39847507-E81A8CD0-03CB-4515-AA45-CFD43BD83D62

Q39847507-ED2F7E78-D223-4FD2-A8B8-87FA655D711E

Q39847507-EE1D79D0-3DA8-45AB-A734-A9FD6E92CAF5

P2860

Q39847507-37CC5AF6-F293-422D-A3A1-C29E3F503E85

Q39847507-45180400-EBD1-46EF-8C1D-DBC1A443AE19

Q39847507-48DF857C-1AAB-4C7F-9694-BE7EA82C1D76

Q39847507-76FF943B-A409-4835-89DA-CC64757D7DD3

Q39847507-7C4A4A9C-4BA5-425A-85BB-0CC7AEFEFA1A

Q39847507-E990C2D8-222F-48A1-8DB0-B4041767E94A

P2888

Q39847507-8AB33B3F-E235-4F0F-98CF-44574CC5D71D

P304

Q39847507-D5FF90B4-B97A-426D-9862-BC11133FAB14

P31

Q39847507-C52AB4D2-AB35-49DE-9563-AA68ADB59FD4

P356

Q39847507-FB5126FB-BAA9-43D9-B84A-3493115543F7

P407

Q39847507-D645DB45-4638-4F72-93EF-E7C7CEE9CF1B

P433

Q39847507-0CBCD792-E508-45FF-B55F-4BED364EA8E1

P478

Q39847507-24262F3F-23D6-44D7-8426-7664E09ABF3A

P577

Q39847507-3E27B806-219C-46AB-83EB-DF10BDE4F450

P5875

Q39847507-8AF3908B-B4E9-4FAE-8303-63EF91C2367E

P698

Q39847507-4EC84E8A-D495-4244-989F-F00A06457D40

P356

P1433

Bone Marrow Transplantation

P1476

Palifermin reduces incidence a ...... em-cell transplant recipients.

@en

P2093

C Urban

http://www.w3.org/2001/XMLSchema#string

G Behre

http://www.w3.org/2001/XMLSchema#string

M Gramatzki

http://www.w3.org/2001/XMLSchema#string

N Schub

http://www.w3.org/2001/XMLSchema#string

P Neumeister

http://www.w3.org/2001/XMLSchema#string

Pb Staber

http://www.w3.org/2001/XMLSchema#string

S Langner

http://www.w3.org/2001/XMLSchema#string

W Grothe

http://www.w3.org/2001/XMLSchema#string

W Linkesch

http://www.w3.org/2001/XMLSchema#string

W Rabitsch

http://www.w3.org/2001/XMLSchema#string

P2860

Palifermin for oral mucositis after intensive therapy for hematologic cancers

Reporting results of cancer treatment

Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology.

Updated clinical practice guidelines for the prevention and treatment of mucositis.

Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

P2888

P304

275-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2008.157

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5350579

http://www.w3.org/2001/XMLSchema#string

P698

18500368

http://www.w3.org/2001/XMLSchema#string